China's biopharma goes global: the NewCo model explained
CST Updated Oct 11, 2025 09:00
The old playbook for Chinese biotech is obsolete. The new strategy is "NewCo" – moving from simple licensing to building global subsidiaries with shared equity and upside.
Per VCBeat's June report:
Chinese drug BD deals have outpaced IPOs for 3 years straight, claiming 30% of the global market.
Over 90% of top MNCs are now actively scouting Chinese pipelines.
$8B+ invested in 2 years: China is the new global hub for pharmaceutical innovation.
This isn't just a trend; it's the essential answer to domestic competition and a tight financing climate.
Watch the full VBTalk to discover how the NewCo model works：